FMT Qualifies as Biological Product, Requires IND Filing for Trials: FDA

The FDA recently informed a group of gastroenterological specialists that fecal microbiota transplantation (FMT), also known as a stool transplant, should be considered a biological product under agency oversight when treating Clostridium difficile (C. difficile) infection.
Clinical Trials Advisor